Table 1 Patient characteristics and... | American Society of Hematology

Table 1

Patient characteristics and parameter estimates from the model fit

Patient no.	1	2	3	4	5	6	7	8	9	10	Average	SD
Characteristics
Age, y	68	70	81	57	51	75	77	55	67	57
Sex*	F	M	M	M	M	M	M	M	M	M
IgVH mutation status†	M	M	M	U	U	U	U	U	M	U
FISH cytogenetics	17p−	neg	11q−	11q−	11q−	11q−	11q−	17p−	11q−	17p−
Karyotype (abnormal)	Yes	Yes	No	Yes	Yes	na	Yes	Yes	Yes	Yes
ZAP70‡	neg	pos	na	neg	neg	pos	pos	neg	na	pos
CD38, >30%	No	Yes	Yes	No	No	Yes	Yes	Yes	No	Yes
ALC, K/µL	39.8	10.6	138.1	19.4	26.8	21.2	0.92	29.4	52.5	7.8
Hb, g/dL	10.8	15.2	9.6	11.2	13.7	13.5	13.8	13.2	12.2	14.8
PLT, K/µL	57	141	72	138	115	68	136	79	104	100
Parameter estimates
Blood, mL	3484	5363	5088	6466	5010	4714	4793	6272	6350	5692
d₂, d⁻¹§	0.002	0.022	0.014	0.016	0.018	0.014	0.010	0.011	0.047	0.018	0.017	0.011
d₁, d⁻¹§	0.027	0.015	0.012	0.047	0.022	0.027	0.022	0.032	0.033	0.035	0.027	0.010
m, d⁻¹§	0.0096	0.0177	0.0146	0.0009	0.0095	0.0061	0.0056	0.0023	0.0088	0.0034	0.008	0.005
α, d⁻¹§	0.037	0.033	0.026	0.047	0.032	0.033	0.028	0.034	0.042	0.039	0.035	0.006
x₀, ×10⁹	3034	3064	7044	30 209	2143	4083	1294	15 452	6156	7711	8019	8799
y₀, ×10⁹	153	58	674	120	217	73	3	521	358	38	221	226
c, ×10⁹	0.4	47.5	94.7	392.1	86.3	35.7	1.0	376.4	507.8	155.9	169.8	185.4
%\|\|	25.9	50	52.6	1.9	29.4	18.2	19.6	6.9	19.3	8.8	23.3	17.0

Patient no.	1	2	3	4	5	6	7	8	9	10	Average	SD
Characteristics
Age, y	68	70	81	57	51	75	77	55	67	57
Sex*	F	M	M	M	M	M	M	M	M	M
IgVH mutation status†	M	M	M	U	U	U	U	U	M	U
FISH cytogenetics	17p−	neg	11q−	11q−	11q−	11q−	11q−	17p−	11q−	17p−
Karyotype (abnormal)	Yes	Yes	No	Yes	Yes	na	Yes	Yes	Yes	Yes
ZAP70‡	neg	pos	na	neg	neg	pos	pos	neg	na	pos
CD38, >30%	No	Yes	Yes	No	No	Yes	Yes	Yes	No	Yes
ALC, K/µL	39.8	10.6	138.1	19.4	26.8	21.2	0.92	29.4	52.5	7.8
Hb, g/dL	10.8	15.2	9.6	11.2	13.7	13.5	13.8	13.2	12.2	14.8
PLT, K/µL	57	141	72	138	115	68	136	79	104	100
Parameter estimates
Blood, mL	3484	5363	5088	6466	5010	4714	4793	6272	6350	5692
d₂, d⁻¹§	0.002	0.022	0.014	0.016	0.018	0.014	0.010	0.011	0.047	0.018	0.017	0.011
d₁, d⁻¹§	0.027	0.015	0.012	0.047	0.022	0.027	0.022	0.032	0.033	0.035	0.027	0.010
m, d⁻¹§	0.0096	0.0177	0.0146	0.0009	0.0095	0.0061	0.0056	0.0023	0.0088	0.0034	0.008	0.005
α, d⁻¹§	0.037	0.033	0.026	0.047	0.032	0.033	0.028	0.034	0.042	0.039	0.035	0.006
x₀, ×10⁹	3034	3064	7044	30 209	2143	4083	1294	15 452	6156	7711	8019	8799
y₀, ×10⁹	153	58	674	120	217	73	3	521	358	38	221	226
c, ×10⁹	0.4	47.5	94.7	392.1	86.3	35.7	1.0	376.4	507.8	155.9	169.8	185.4
%\|\|	25.9	50	52.6	1.9	29.4	18.2	19.6	6.9	19.3	8.8	23.3	17.0

All values were at baseline values, prior to start of ibrutinib.

ALC, absolute lymphocyte count; FISH, fluorescence in situ hybridization; IgVH, immunoglobulin heavy variable chain; Hb, hemoglobin; na, not available; neg, negative; pos, positive; PLT, platelet; SD, standard deviation; ZAP70, ζ-chain-associated protein kinase 70.

F, female; M, male.

†

M, mutated; U, unmutated.

‡

Zap-70 by immunohistochemistry.

d⁻¹ stands for “per day.”

Percent (%) indicates percent of pretreatment tissue tumor burden that is redistributed into the blood during treatment.

View Large

This Feature Is Available To Subscribers Only